2015-2022 流感疫苗株重组抗原-环球风云-资讯-生物在线

2015-2022 流感疫苗株重组抗原

作者:北京义翘神州科技有限公司 2021-05-07T16:04 (访问量:15415)

流行性感冒是一种常见的季节性可传染的呼吸道疾病,由流感病毒引起。目前,已鉴定的流感病毒有4类,包括A型,B型,C型和D型。其中,A型和B型流感病毒可引起大范围的流行性感冒,因此也更加受到生物医学界科学家们的关注。值得关注的是,以往的几次全球性流感大流行基本都是由A型流感病毒引起的,比如Hong Kong flu (1968–1969),H1N1/09 flu pandemic (2009–2010)分别由A/Hong Kong/1/1968 (H3N2) 和 A/California/04/09 (H1N1) 导致。

接种流感疫苗是预防流行性感冒的有效方法。每年WHO都会根据新分离出的毒株检测数据以及上一个季节流感疫苗的性能选择3-4种不同的流感毒株作为疫苗株。近几十年,流感疫苗均为4价或者3价,可预防的流感包括1种H1N1、1种H3N2以及1种或者2种B型流感病毒(Yamagata 或/和 Victoria )。



义翘神州ProVir病毒抗原库中覆盖了近600+流感病毒抗原,包括重组HA, NA, NP以及更多流感抗原,覆盖了近些年WHO推荐的所有流感疫苗株,可用于检测分析疫苗介导的抗体应答反应。除此之外,我们还开发了80余种流感病毒单克隆抗体试剂,可用于相关检测试剂开发。
2021-2022流感疫苗株相关重组蛋白产品
A/Victoria/2570/2019 (H1N1)
Recommended for Egg-based (quadrivalent,trivalent) Vaccine
HA: 40787-V08H, 40787-V08H1
NA: 40785-V08B
NP: 40774-V08B
A/Wisconsin/588/2019 (H1N1)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40787-V08H, 40787-V08H1
NA: 40785-V08B
NP: 40774-V08B
B/Washington/02/2019
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40722-V08H
NA: 40790-V08B
NP: 40755-V08B
B/Phuket/3073/2013
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
A/Cambodia/E0826360/2020 (H3N2)
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40789-V08H, 40789-V08H1
NA: 40784-V08B
NP: 40778-V08B (Under Development)
2020-2021流感疫苗株相关重组蛋白产品
A/Guangdong-Maonan/SWL1536/2019 (H1N1)
Recommended for Egg-based (quadrivalent, trivalent) Vaccine
HA: 40717-V08H
NP: 40723-V08B
A/Hong Kong/2671/2019 (H3N2)
Recommended for Egg-based (quadrivalent, trivalent) Vaccine
HA: 40721-V08H
NP: 40753-V08B
A/Hawaii/70/2019 (H1N1)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40717-V08H
NP: 40724-V08B
A/Hong Kong/45/2019 (H3N2)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA:40765-V08H (Under Development)
NP: 40754-V08B
B/Phuket/3073/2013
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
B/Washington/02/2019
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40722-V08H
NP: 40755-V08B
2019-2020流感疫苗株相关重组蛋白产品
A/Brisbane/02/2018 (H1N1)
Recommended for Egg-based (quadrivalent) Vaccine
HA: 40719-V08H
NP: 40776-V08B
A/Kansas/14/2017 (H3N2)
Recommended for Egg-based (quadrivalent) Vaccine
HA: 40720-V08H
NP: 40779-V08B
B/Phuket/3073/2013
Recommended for Egg-based (quadrivalent) Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
B/Colorado/06/2017
Recommended for Egg-based (quadrivalent); trivalent Vaccine
HA: 40581-V08H
NP: 40782-V08B (Under Development)
2018-2019流感疫苗株相关重组蛋白产品
A/Michigan/45/2015 (H1N1)
Recommended for quadrivalent Vaccine
HA: 40567-V08H1
NA: 40568-V08B
NP: 40777-V08B
A/Singapore/INFIMH-16-0019/2016 (H3N2)
Recommended for quadrivalent Vaccine
HA: 40580-V08H
NP: 40779-V08B
B/Colorado/06/2017
Recommended for quadrivalent; trivalent Vaccine
HA: 40581-V08H
NP: 40782-V08B (Under Development)
B/Phuket/3073/2013
Recommended for quadrivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
2017-2018流感疫苗株相关重组蛋白产品
A/Michigan/45/2015 (H1N1)
Recommended for trivalent Vaccine
HA: 40567-V08H1
NA: 40568-V08B
NP: 40777-V08B
A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine
HA: 40555-V08B
NA: 40569-V08B
NP: 40781-V08B
B/Brisbane/60/2008
Recommended for trivalent Vaccine
HA: 40016-V08B
NA: 40203-VNAHC
NP: 40783-V08B (Under Development)
B/Phuket/3073/2013
Recommended for quadrivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
2016-2017流感疫苗株相关重组蛋白产品
A/California/7/2009 (H1N1)
Recommended for trivalent Vaccine
HA: 11085-V08B
NP: 40205-V08B
A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine
HA: 40555-V08B
NA: 40569-V08B
NP: 40781-V08B
B/Brisbane/60/2008
Recommended for trivalent Vaccine
HA: 40016-V08B
NA: 40203-VNAHC
NP: 40783-V08B (Under Development)
B/Phuket/3073/2013
Recommended for trivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
2015-2016流感疫苗株相关重组蛋白产品
A/California/7/2009 (H1N1)
Recommended for trivalent Vaccine
HA: 11085-V08B
NP: 40205-V08B
A/Switzerland/9715293/2013 (H3N2)
Recommended for trivalent Vaccine
HA: 40497-V08B
NP: 40499-V08B
B/Brisbane/60/2008
Recommended for quadrivalent Vaccine
HA: 40016-V08B
NA: 40203-VNAHC
NP: 40783-V08B (Under Development)
B/Phuket/3073/2013
Recommended for trivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
北京义翘神州科技有限公司 商家主页

地 址: 北京亦庄东区科创十街18号院9号楼306室

联系人: 客服部

电 话: 400-890-9989

传 真: 010-50911666

Email:marketing@sinobiological.cn

相关咨询

义翘神州与镁伽达成深度战略合作,全自动质粒构建系统项目正式落地 (2023-04-20T08:30 浏览数:10251)

义翘神州年中促销活动正式开始啦 (2022-07-01T16:56 浏览数:11041)

义翘神州成功开发“奥密克戎”变异株重组蛋白 (2021-12-03T09:57 浏览数:9997)

第五届青科会广发“英雄令”,诚邀麒麟之才共襄科研赛事 (2021-09-16T14:51 浏览数:10290)

义翘神州成功上市,开启发展新征程 (2021-08-16T11:05 浏览数:16517)

可识别多种抗原的流感广谱抗体 (2021-08-02T10:05 浏览数:10380)

1000+重组病毒抗原库:ProVir (2021-06-25T15:41 浏览数:17677)

突变株不断出现,我们应该如何应对 (2021-06-02T14:46 浏览数:7091)

超全的新冠病毒突变蛋白试剂库 (2021-06-02T14:33 浏览数:10473)

2015-2022 流感疫苗株重组抗原 (2021-05-07T16:04 浏览数:15415)

ADVERTISEMENT